Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
17beta-estradiol 17-dehydrogenase deficiency
Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3).
17beta-estradiol 17-dehydrogenase deficiency
Hydroxysteroid (17?) dehydrogenase 12 is essential for metabolic homeostasis in adult mice.
17beta-estradiol 17-dehydrogenase deficiency
Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
3beta-hydroxysteroid dehydrogenase/delta5-->4-isomerase activity associated with the human 17beta-hydroxysteroid dehydrogenase type 2 isoform.
Adenocarcinoma
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
Adenoma
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Adenomyosis
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Adrenal Insufficiency
Four patients with D-bifunctional protein (DBP) deficiency: Expanding the phenotypic spectrum of a highly variable disease.
Adrenocortical Carcinoma
Overexpression of HSD17B4 exerts tumor suppressive function in adrenocortical carcinoma and is not associated with hormone excess.
Ataxia
Autonomous Purkinje cell axonal dystrophy causes ataxia in peroxisomal multifunctional protein-2 deficiency.
Ataxia
Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome.
Ataxia
Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency.
Ataxia
Severe manifestation of Leber's hereditary optic neuropathy due to 11778G>A mtDNA mutation in a female with hypoestrogenism due to Perrault syndrome.
Breast Diseases
New development in intracrinology of breast carcinoma.
Breast Neoplasms
1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase.
Breast Neoplasms
17-beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
Breast Neoplasms
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
Breast Neoplasms
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Breast Neoplasms
17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
Breast Neoplasms
17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
Breast Neoplasms
A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
Breast Neoplasms
A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer.
Breast Neoplasms
Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Breast Neoplasms
Acetylation targets HSD17B4 for degradation via the CMA pathway in response to estrone.
Breast Neoplasms
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Breast Neoplasms
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Breast Neoplasms
Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Breast Neoplasms
DNA methylation marker to estimate the breast cancer cell fraction in DNA samples.
Breast Neoplasms
Effect of retinoic acid and palm oil carotenoids on oestrone sulphatase and oestradiol-17beta hydroxysteroid dehydrogenase activities in MCF-7 and MDA-MB-231 breast cancer cell lines.
Breast Neoplasms
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Breast Neoplasms
Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme.
Breast Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.
Breast Neoplasms
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study.
Breast Neoplasms
Expression of COX-2 and steroid converting enzymes in breast cancer.
Breast Neoplasms
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients.
Breast Neoplasms
Hormonal carcinogenesis.
Breast Neoplasms
Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.
Breast Neoplasms
Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts.
Breast Neoplasms
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Breast Neoplasms
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
Breast Neoplasms
Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Breast Neoplasms
Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer.
Breast Neoplasms
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
Breast Neoplasms
Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Breast Neoplasms
New development in intracrinology of breast carcinoma.
Breast Neoplasms
Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.
Breast Neoplasms
PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer.
Breast Neoplasms
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
Breast Neoplasms
Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial).
Breast Neoplasms
Progestins and cancer.
Breast Neoplasms
Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients.
Breast Neoplasms
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Breast Neoplasms
Sex steroid-producing enzymes in human breast cancer.
Breast Neoplasms
Structure and function of 17beta-hydroxysteroid dehydrogenase type 1 and type 2.
Breast Neoplasms
Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+.
Breast Neoplasms
The gene for 17 beta-hydroxysteroid dehydrogenase maps to human chromosome 17, bands q12-q21, and shows an RFLP with ScaI.
Breast Neoplasms
The regulation of hydroxysteroid 17?-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer.
Breast Neoplasms
Type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3) inhibition and potential anti-proliferative activity of cholest-4-ene-3,6-dione in MCF-7 breast cancer cells.
Carcinoma
17? hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.
Carcinoma
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Carcinoma
17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Carcinoma
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase.
Carcinoma
High Expression of 17?-hydroxysteroid Dehydrogenase Type 2 is Associated with a Better Prognosis in Urothelial Carcinoma of the Urinary Tract.
Carcinoma
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Carcinoma
Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue.
Carcinoma
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Carcinoma
Overexpression of HSD17B4 exerts tumor suppressive function in adrenocortical carcinoma and is not associated with hormone excess.
Carcinoma
[Altered expression of the HSD17B4 gene in esophageal squamous cell carcinoma and loss of heterozygosity analysis]
Carcinoma, Ductal
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Carcinoma, Ductal
New development in intracrinology of breast carcinoma.
Carcinoma, Endometrioid
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Carcinoma, Hepatocellular
Association of Genetic Polymorphisms in HSD17B1, HSD17B2 and SHBG Genes with Hepatocellular Carcinoma Risk.
Carcinoma, Hepatocellular
NF-?B increased expression of 17?-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol.
Carcinoma, Intraductal, Noninfiltrating
New development in intracrinology of breast carcinoma.
Carcinoma, Non-Small-Cell Lung
HSD17B4, ACAA1, and PXMP4 in Peroxisome Pathway Are Down-Regulated and Have Clinical Significance in Non-small Cell Lung Cancer.
Carcinoma, Ovarian Epithelial
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
Carcinoma, Small Cell
Overexpression of HSD17B4 exerts tumor suppressive function in adrenocortical carcinoma and is not associated with hormone excess.
Carcinoma, Squamous Cell
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Carcinoma, Squamous Cell
Intracellular regulation of 17 beta-hydroxysteroid dehydrogenase type 2 catalytic activity in A431 cells.
Carcinoma, Squamous Cell
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Cerebellar Ataxia
Slowly progressive d-bifunctional protein deficiency with survival to adulthood diagnosed by whole-exome sequencing.
CHARGE Syndrome
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Choriocarcinoma
Characterization of 17 beta-hydroxysteroid dehydrogenase type 1 in choriocarcinoma cells: regulation by basic fibroblast growth factor.
Choriocarcinoma
Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor.
Choriocarcinoma
Organotin compounds enhance 17beta-hydroxysteroid dehydrogenase type I activity in human choriocarcinoma JAr cells: potential promotion of 17beta-estradiol biosynthesis in human placenta.
Colonic Neoplasms
17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.
Colonic Neoplasms
Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4).
Colorectal Neoplasms
Functional genetic variant of HSD17B12 in the fatty acid biosynthesis pathway predicts the outcome of colorectal cancer.
Colorectal Neoplasms
Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women.
Dengue
Very-long-chain fatty acid metabolic capacity of 17-beta-hydroxysteroid dehydrogenase type 12 (HSD17B12) promotes replication of hepatitis C virus and related flaviviruses.
Diabetes Mellitus
[Serum levels of 17-beta estradiol dehydrogenase in pregnancies complicated by diabetes mellitus]
Diabetes Mellitus, Type 2
An Integrative Phenotype-Genotype Approach Using Phenotypic Characteristics from the UAE National Diabetes Study Identifies HSD17B12 as a Candidate Gene for Obesity and Type 2 Diabetes.
Disorder of Sex Development, 46,XY
Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3).
Dyslipidemias
Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway.
Endometrial Hyperplasia
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Endometrial Neoplasms
17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Endometrial Neoplasms
Divergent effects of retinoic acids on the expression of ERalpha and 17beta-hydroxysteroid dehydrogenase type 2 in endometrial carcinoma cells (RL 95-2).
Endometrial Neoplasms
Failure of progestins to induce estradiol dehydrogenase activity in endometrial carcinoma, in vitro.
Endometrial Neoplasms
Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.
Endometrial Neoplasms
Menopausal endocrinology and management.
Endometrial Neoplasms
Progestins and cancer.
Endometrial Neoplasms
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Endometrial Neoplasms
The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma.
Endometrial Neoplasms
[Studies on estradiol dehydrogenase activity in the human uterine endometrium]
Endometriosis
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Endometriosis
Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection.
Endometriosis
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.
Endometriosis
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
Endometriosis
Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line.
Endometriosis
Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance.
Endometriosis
Estrogen metabolizing enzymes in endometrium and endometriosis.
Endometriosis
Expression of 17beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis.
Endometriosis
HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in infertile women with endometriosis.
Endometriosis
Induction of endometriosis in the marmoset monkey (Callithrix jacchus).
Endometriosis
Mechanisms of excessive estrogen formation in endometriosis.
Endometriosis
Role of aromatase in endometrial disease.
Endometriosis
Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis.
Endometriosis
Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism.
Esophageal Squamous Cell Carcinoma
[Altered expression of the HSD17B4 gene in esophageal squamous cell carcinoma and loss of heterozygosity analysis]
Flaviviridae Infections
Very-long-chain fatty acid metabolic capacity of 17-beta-hydroxysteroid dehydrogenase type 12 (HSD17B12) promotes replication of hepatitis C virus and related flaviviruses.
Hearing Loss
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Hearing Loss
Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome.
Hearing Loss
Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency.
Hearing Loss, Sensorineural
Four patients with D-bifunctional protein (DBP) deficiency: Expanding the phenotypic spectrum of a highly variable disease.
Hepatitis C
Very-long-chain fatty acid metabolic capacity of 17-beta-hydroxysteroid dehydrogenase type 12 (HSD17B12) promotes replication of hepatitis C virus and related flaviviruses.
Hydatidiform Mole
[Serum and tissue 17 beta hydroxysteroid dehydrogenase and estrogens in hydatidiform mole]
Hydatidiform Mole
[Serum levels of 17-beta estradiol dehydrogenase in pregnancies complicated by hydatidiform mole and in twin pregnancies]
Hypospadias
Fine mapping analysis confirms and strengthens linkage of four chromosomal regions in familial hypospadias.
Hypospadias
Lack of defects in androgen production in children with hypospadias.
Infertility
The hydroxysteroid (17?) dehydrogenase family gene HSD17B12 is involved in the prostaglandin synthesis pathway, the ovarian function, and regulation of fertility.
Infertility
Transgenic male mice expressing human hydroxysteroid dehydrogenase 2 indicate a role for the enzyme independent of its action on sex steroids.
Intellectual Disability
Severe manifestation of Leber's hereditary optic neuropathy due to 11778G>A mtDNA mutation in a female with hypoestrogenism due to Perrault syndrome.
Kallmann Syndrome
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Leiomyoma
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Leiomyoma
Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma.
Leiomyoma
Polymorphisms in genes HSD17B1 and HSD17B2 and uterine leiomyoma risk in Chinese women.
Leukemia
T cell recognition of Moloney leukemia virus proteins. III. T cell proliferative responses against gp70 are associated with the production of a lymphokine inducing 20 alpha-hydroxysteroid dehydrogenase in splenic lymphocytes.
Liver Diseases, Alcoholic
Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
Liver Neoplasms
17??hydroxysteroid dehydrogenase 4 induces liver cancer proliferation?associated genes via STAT3 activation.
Liver Neoplasms
AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies.
Liver Neoplasms
Comment on: Correlation between HSD17B4 expression in rat liver cancer tissues and inflammation or proliferation.
Liver Neoplasms
Correlation between HSD17B4 expression in rat liver cancer tissues and inflammation or proliferation.
Liver Neoplasms
NF-?B increased expression of 17?-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol.
Lung Neoplasms
Altered expression of 17???hydroxysteroid dehydrogenase type 2 and its prognostic significance in non?small cell lung cancer.
Lung Neoplasms
HSD17B4, ACAA1, and PXMP4 in Peroxisome Pathway Are Down-Regulated and Have Clinical Significance in Non-small Cell Lung Cancer.
Lymphatic Metastasis
Expression of 17?-hydroxysteroid dehydrogenase type 2 is associated with some clinicopathological features in gastric cancer.
Lymphoma
Influence of genotype and the organ of origin on the subtype of T-cell in Moloney lymphomas induced by transfer of preleukemic cells from athymic and thymus-bearing mice.
Mandibulofacial Dysostosis
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Mania
Polymorphisms in AKR1C4 and HSD3B2 and differences in serum DHEAS and progesterone are associated with paranoid ideation during mania or hypomania in bipolar disorder.
Megalencephaly
Four patients with D-bifunctional protein (DBP) deficiency: Expanding the phenotypic spectrum of a highly variable disease.
Muscle Hypotonia
Four patients with D-bifunctional protein (DBP) deficiency: Expanding the phenotypic spectrum of a highly variable disease.
Neoplasm Metastasis
Expression of 17?-hydroxysteroid dehydrogenase type 2 is associated with some clinicopathological features in gastric cancer.
Neoplasm Metastasis
High Expression of 17?-hydroxysteroid Dehydrogenase Type 2 is Associated with a Better Prognosis in Urothelial Carcinoma of the Urinary Tract.
Neoplasm Metastasis
Steroid-converting enzymes in human ovarian carcinomas.
Neoplasms
17? hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.
Neoplasms
17??hydroxysteroid dehydrogenase 4 induces liver cancer proliferation?associated genes via STAT3 activation.
Neoplasms
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
Neoplasms
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Neoplasms
17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
Neoplasms
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Neoplasms
17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
Neoplasms
17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
Neoplasms
20 alpha-hydroxysteroid dehydrogenase activity in canine spontaneous neoplasms.
Neoplasms
A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Neoplasms
Altered expression of 17???hydroxysteroid dehydrogenase type 2 and its prognostic significance in non?small cell lung cancer.
Neoplasms
Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.
Neoplasms
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.
Neoplasms
Correlation between HSD17B4 expression in rat liver cancer tissues and inflammation or proliferation.
Neoplasms
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary.
Neoplasms
Cytosolic 20 alpha-hydroxysteroid dehydrogenase activity in spontaneous neoplasms in the dog and cat.
Neoplasms
Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4).
Neoplasms
Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues.
Neoplasms
DNA methylation marker to estimate the breast cancer cell fraction in DNA samples.
Neoplasms
Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase.
Neoplasms
Expression of 17?-hydroxysteroid dehydrogenase type 2 is associated with some clinicopathological features in gastric cancer.
Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.
Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Neoplasms
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study.
Neoplasms
Functional silencing of HSD17B2 in prostate cancer promotes disease progression.
Neoplasms
Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
Neoplasms
Gene expression of androgen metabolising enzymes in benign prostatic hyperplasia.
Neoplasms
High mRNA levels of 17?-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer.
Neoplasms
Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.
Neoplasms
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Neoplasms
Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue.
Neoplasms
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
Neoplasms
Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer.
Neoplasms
Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
Neoplasms
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Neoplasms
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
Neoplasms
NF-?B increased expression of 17?-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol.
Neoplasms
Overexpression of HSD17B4 exerts tumor suppressive function in adrenocortical carcinoma and is not associated with hormone excess.
Neoplasms
Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.
Neoplasms
Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial).
Neoplasms
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Neoplasms
Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients.
Neoplasms
Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Neoplasms
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Neoplasms
Steroid metabolism and steroid receptors in dimethylbenz(a)anthracene-induced rat mammary tumors.
Neoplasms
Steroid metabolism in normal mammary gland and in the dimethylbenzanthracene-induced mammary tumor of rats.
Neoplasms
Steroid-converting enzymes in human ovarian carcinomas.
Neoplasms
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
Neoplasms
The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
Neoplasms
Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase.
Neoplasms
[Altered expression of the HSD17B4 gene in esophageal squamous cell carcinoma and loss of heterozygosity analysis]
Nephritis, Hereditary
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Neuroblastoma
Common genetic variants in NEFL influence gene expression and neuroblastoma risk.
Neuroblastoma
HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population.
Neuroblastoma
Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.
Obesity
An Integrative Phenotype-Genotype Approach Using Phenotypic Characteristics from the UAE National Diabetes Study Identifies HSD17B12 as a Candidate Gene for Obesity and Type 2 Diabetes.
Osteosarcoma
Effects of 20 alpha-hydroxysteroid dehydrogenase and its inhibitors on canine osteosarcoma cell growth in vitro.
Ovarian Neoplasms
Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Ovarian Neoplasms
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
Peripheral Nervous System Diseases
Four patients with D-bifunctional protein (DBP) deficiency: Expanding the phenotypic spectrum of a highly variable disease.
Peripheral Nervous System Diseases
Slowly progressive d-bifunctional protein deficiency with survival to adulthood diagnosed by whole-exome sequencing.
Pituitary Neoplasms
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Polycystic Ovary Syndrome
PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
Pregnancy, Tubal
Expression of P450 aromatase and 17beta-hydroxysteroid dehydrogenase type 1 at fetal-maternal interface during tubal pregnancy.
Primary Ovarian Insufficiency
Epistasis between the HSD17B4 and TG polymorphisms is associated with premature ovarian failure.
Prolactinoma
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Prostatic Neoplasms
Acetylation-mediated degradation of HSD17B4 regulates the progression of prostate cancer.
Prostatic Neoplasms
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.
Prostatic Neoplasms
Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.
Prostatic Neoplasms
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase.
Prostatic Neoplasms
Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.
Prostatic Neoplasms
Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues.
Prostatic Neoplasms
Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells.
Prostatic Neoplasms
Functional silencing of HSD17B2 in prostate cancer promotes disease progression.
Prostatic Neoplasms
Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
Prostatic Neoplasms
HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer.
Prostatic Neoplasms
Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human prostate cancer cells.
Prostatic Neoplasms
Steroidogenic enzymes and stem cell markers are up-regulated during androgen deprivation in prostate cancer.
Protein Deficiency
D-bifunctional protein deficiency: a cause of neonatal onset seizures and hypotonia.
Protein Deficiency
Diagnosis of D-Bifunctional Protein Deficiency through Whole-Genome Sequencing: Implications for Cost-Effective Care.
Protein Deficiency
First Case of Peroxisomal D-bifunctional Protein Deficiency with Novel HSD17B4 Mutations and Progressive Neuropathy in Korea.
Protein Deficiency
Heterozygous mutations in HSD17B4 cause juvenile peroxisomal D-bifunctional protein deficiency.
Protein Deficiency
Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency.
Protein Deficiency
Rapid whole-genome sequencing identifies a homozygous novel variant, His540Arg, in HSD17B4 resulting in D-bifunctional protein deficiency disorder diagnosis.
Protein Deficiency
Two Novel HSD17B4 Heterozygous Mutations in Association With D-Bifunctional Protein Deficiency: A Case Report and Literature Review.
Puberty, Precocious
Identification and Characterization of lncRNA and mRNA in Testes of Landrace and Hezuo Boars.
Rectal Neoplasms
The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
Sarcoma
Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.
Seizures
Diagnosis of D-Bifunctional Protein Deficiency through Whole-Genome Sequencing: Implications for Cost-Effective Care.
Spasms, Infantile
Four patients with D-bifunctional protein (DBP) deficiency: Expanding the phenotypic spectrum of a highly variable disease.
Spinocerebellar Ataxias
Biallelic mutation of HSD17B4 induces middle age-onset spinocerebellar ataxia.
Squamous Cell Carcinoma of Head and Neck
Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays.
Stomach Neoplasms
Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk.
Testicular Neoplasms
Effect modification of endocrine disruptors and testicular germ cell tumour risk by hormone-metabolizing genes.
Thymoma
Estrogen inhibits cell proliferation through in situ production in human thymoma.
Uremia
Different vitamin D receptor agonists exhibit differential effects on endothelial function and aortic gene expression in 5/6 nephrectomized rats.
Usher Syndromes
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Uterine Hemorrhage
Menopausal endocrinology and management.
Waardenburg Syndrome
Laser-capture micro dissection combined with next-generation sequencing analysis of cell type-specific deafness gene expression in the mouse cochlea.
Zellweger Syndrome
Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.1.1.62 17beta-estradiol 17-dehydrogenase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
